GlassScriptPhysician profile
Tommie Simon
NPI 1043653264
$54,660.81
in general payments reported to CMS, 2019-2025
17 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $171 · 2021: $680 · 2022: $35K · 2023: $18K · 2024: $156 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,800 · Honoraria: $6,750 · Travel and Lodging: $3,788 · Food and Beverage: $1,306 · Education: $18.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,800.00 |
| Honoraria | $6,750.00 |
| Travel and Lodging | $3,787.88 |
| Food and Beverage | $1,305.78 |
| Education | $18.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36,996.45 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Horizon Therapeutics Plc | $15,057.90 | 2019-2023 | Krystexxa |
| Amgen INC. | $556.88 | 2019-2025 | Tavneos, Otezla |
| Janssen Biotech, INC. | $301.04 | 2020-2024 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $217.07 | 2021-2023 | Benlysta |
| Janssen Scientific Affairs, LLC | $215.39 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $215.16 | 2020-2025 | |
| Genzyme Corporation | $202.71 | 2019-2024 | |
| Ucb, INC. | $197.08 | 2019-2023 | Cimzia |
| Lilly USA, LLC | $191.73 | 2021-2023 | Taltz |
| Astrazeneca Pharmaceuticals LP | $167.06 | 2022-2024 | Saphnelo |
| Genentech USA, INC. | $135.90 | 2021-2023 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $96.07 | 2021-2022 | |
| Genentech, INC. | $47.95 | 2020 | |
| Celgene Corporation | $26.90 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $23.43 | 2022 | |
| Pfizer INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tommie Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.